GlassScriptPhysician profile
Babak Bedayat
NPI 1083896955
$6,191.48
in general payments reported to CMS, 2019-2025
34 companies · $1,807 in 2025
The $1,807 reported for 2025 was more than what 76% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,706 · 2020: $588 · 2021: $679 · 2022: $649 · 2023: $460 · 2024: $301 · 2025: $1,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,689 · Travel and Lodging: $880.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.56 |
| Travel and Lodging | $880.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $1,588.08 | 2019-2020 | |
| Boston Scientific Corporation | $1,302.93 | 2020-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Medtronic, INC. | $724.45 | 2021-2025 | Inceptiv |
| Ibsa Pharma INC. | $623.52 | 2021-2025 | Tirosint, Tirosint, Licart |
| Lilly USA, LLC | $271.39 | 2020-2025 | Mounjaro, Zepbound, Baqsimi |
| Biohaven Pharmaceutical Holding Company LTD. | $228.47 | 2022 | |
| Nevro Corp. | $201.51 | 2020 | |
| Pfizer INC. | $156.80 | 2023-2024 | |
| Biogen, INC. | $126.10 | 2021-2022 | |
| Corcept Therapeutics | $107.56 | 2020-2022 | |
| Amgen INC. | $86.63 | 2019-2022 | |
| Avanos Medical | $85.35 | 2021-2024 | Standard Rf Disposables |
| Novo Nordisk INC | $82.98 | 2020-2024 | Wegovy |
| Abbott Laboratories | $71.10 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $58.72 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $48.87 | 2019 | |
| Collegium Pharmaceutical, INC. | $45.08 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.70 | 2022-2023 | Jardiance |
| Abbvie INC. | $37.32 | 2023-2025 | Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $29.69 | 2023 | |
| Watermark Medical, INC. | $24.92 | 2024 | |
| Exact Sciences Corporation | $24.20 | 2023 | Cologuard Collection Kit |
| Genzyme Corporation | $24.11 | 2020 | |
| Xeris Pharmaceuticals, INC. | $24.07 | 2021 | |
| Antares Pharma, INC. | $21.93 | 2023 | Xyosted, Tlando, Nocdurna |
| Amneal Pharmaceuticals LLC | $21.82 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $21.07 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $20.90 | 2022 | |
| Mylan Specialty L.P. | $20.12 | 2023 | Yupelri |
| Acella Pharmaceuticals, LLC | $16.24 | 2022 | |
| Avion Pharmaceuticals | $14.83 | 2022 | |
| Ucb, INC. | $13.76 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.15 | 2019 | |
| Electronic Waveform Lab, INC. | $11.11 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Babak Bedayat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.